Revolution Medicines Starts Phase 3 Lung Cancer Trial

The clinical trial investigates the effectiveness of zoldonrasib in patients with metastatic non-small cell lung cancer.

Updated on Oct. 20, 2026 in Cancer

A close-up of a clean laboratory glass vessel on a metallic surface, representing clinical pharmaceutical research. — Revolution Medicines has initiated a Phase 3 clinical trial for zoldonrasib, targeting metastatic non-small cell lung cancer in untreated patients. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to prioritize long-term patient health when developing new cancer treatment options?

Revolution Medicines has begun patient treatment in a Phase 3 clinical trial evaluating zoldonrasib for previously untreated metastatic RAS G12D non-squamous non-small cell lung cancer. The study combines zoldonrasib with pembrolizumab and chemotherapy to determine its efficacy compared to standard treatments.

Why it matters

This trial addresses a specific mutation in a patient population that accounts for 80% to 85% of all lung cancers. Preliminary data indicated antitumor activity and a favorable safety profile, prompting this final stage of testing.

The study targets RAS G12D mutations, which appear in 4% of non-small cell lung cancer cases, a subset of the 30% of lung cancers driven by RAS mutations. The trial tracks progression-free survival as its primary endpoint.

The players

Revolution Medicines

A clinical-stage precision oncology company based in Redwood City, California, that develops therapies targeting RAS-addicted cancers.

The details

The RASolve 308 trial utilizes a randomized, double-blind design to evaluate the drug, which functions by binding to cyclophilin A to inhibit the active RAS G12D mutation. Researchers will monitor secondary endpoints, including overall survival and patient-reported outcomes, to assess the therapy.

Patient treatment in the Phase 3 trial began on October 20, 2026.

The Big Picture

This trial extends the ongoing industry-wide focus on RAS-targeted therapy development programs by advancing a specific inhibitor into late-stage human testing. The study represents a major shift from identifying RAS-driven mechanisms toward validating clinical efficacy in large patient populations.

Patients with previously untreated metastatic RAS G12D non-small cell lung cancer may now have access to this experimental combination therapy through the study. Participation in the clinical trial provides access to emerging treatments while requiring regular monitoring for progression-free survival.

The takeaway

This study highlights the growing trend toward using precision medicine to target specific genetic mutations in lung cancer. Patients should consult with their oncologists to determine if they meet the specific genetic criteria required to participate in clinical trials for new targeted therapies.